AKT1 and B-cell chronic lymphocytic leukemia: Recently, Spina et al., based on the observations of 31 high-risk CLL patients treated with ibrutinib within the IOSI-EMA-001 study (#NCT0287617), proposed that clonal shifts promote cells with constant activations of AKT and ERK and non-canonical NF-κB pathways, preventing their death [101].